Association of lipid accumulation products with testosterone deficiency in adult American men: A cross-sectional study.
NHANES
lipid accumulation products (LAP)
testosterone
testosterone deficiency
triglyceride-glucose (TyG)
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
03
11
2022
received:
27
09
2022
accepted:
24
11
2022
pubmed:
28
11
2022
medline:
17
2
2023
entrez:
27
11
2022
Statut:
ppublish
Résumé
Testosterone deficiency and changes in testosterone levels are important in men's health and may be associated with fat accumulation. In order to investigate the connection between testosterone and fat accumulation in adult males, we employed lipid accumulation product and compared it to triglyceride-glucose and Homeostasis Model Assessment of Insulin Resistance. An intersecting surface research of participators from 2013 to 2014 was carried out using National Health and Nutrition Examination Survey, in addition, participants from 2015 to 2016 were selected. Using multivariate adjusted logistic regression, the connection between lipid accumulation product, testosterone levels, and testosterone insufficiency was investigated, smoothed curve fitting was calculated to integrate non-linear relationships, and subgroup analysis was performed to identify sensitive populations. After removing all potential confounders, testosterone levels in 1651 subjects tended to decrease with increasing continuous variable lipid accumulation product (β = -0.49, 95% confidence interval [-0.77, -0.22], p = 0.0005) and adding the chance of testosterone deficiency (odds ratio = 1.01, 95% confidence interval [1.01, 1.01], p < 0.0001). In the lipid accumulation product quartile, testosterone levels decreased the most (β = -77.65, 95% confidence interval [-110.99, -44.31], p < 0.0001) and the risk of testosterone deficiency was highest (odds ratio = 2.76, 95% confidence interval [1.47, 5.20], p = 0.0016). The area under the curve values were 0.718 (95% confidence interval: 0.688-0.750) for lipid accumulation product, 0.723 (95% confidence interval: 0.689-0.756) for Homeostasis Model Assessment of Insulin Resistance, and 0.673 (95% confidence interval: 0.640-0.708) for triglyceride-glucose, with no statistical difference between lipid accumulation product and Homeostasis Model Assessment of Insulin Resistance comparisons. The cut-off value of lipid accumulation product ≥52.408 predicted testosterone deficiency with good sensitivity and specificity. Higher lipid accumulation product was linked to a higher incidence of testosterone loss and inadequate, especially in hypertensive and non-smoker. Lipid accumulation product is a better predictor of testosterone deficiency than triglyceride-glucose and does not differ significantly from the Homeostasis Model Assessment of Insulin Resistance phase.
Substances chimiques
Blood Glucose
0
Glucose
IY9XDZ35W2
Triglycerides
0
Testosterone
3XMK78S47O
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
551-560Informations de copyright
© 2022 American Society of Andrology and European Academy of Andrology.
Références
Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10):3007-3019. https://doi.org/10.1210/jc.2011-1137
Morgentaler A, Traish A. The history of testosterone and the evolution of its therapeutic potential. Sex Med Rev. 2020;8(2):286-296. http://doi.org/10.1016/j.sxmr.2018.03.002
Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A reappraisal of testosterone's binding in circulation: physiological and clinical implications. Endocr Rev. 2017;38(4):302-324. http://doi.org/10.1210/er.2017-00025
Halpern JA, Brannigan RE. Testosterone deficiency. JAMA. 2019;322(11):1116. http://doi.org/10.1001/jama.2019.9290
Kwong JCC, Krakowsky Y, Grober E. Testosterone deficiency: a review and comparison of current guidelines. J Sex Med. 2019;16(6):812-820. http://doi.org/10.1016/j.jsxm.2019.03.262
Barbonetti A, D'Andrea S, Francavilla S. Testosterone replacement therapy. Andrology. 2020;8(6):1551-1566. http://doi.org/10.1111/andr.12774
Tsametis CP, Isidori AM. Testosterone replacement therapy: for whom, when and how? Metabolism. 2018;86:69-78. http://doi.org/10.1016/j.metabol.2018.03.007
Morgentaler A. Testosterone deficiency and cardiovascular mortality. Asian J Androl. 2015;17(1):26-31. http://doi.org/10.4103/1008-682x.143248
Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med. 2011;124(7):578-587. http://doi.org/10.1016/j.amjmed.2010.12.027
Mamtani MR, Kulkarni HR. Predictive performance of anthropometric indexes of central obesity for the risk of type 2 diabetes. Arch Med Res. 2005;36(5):581-589. http://doi.org/10.1016/j.arcmed.2005.03.049
Nevill AM, Stewart AD, Olds T, Duncan MJ. A new waist-to-height ratio predicts abdominal adiposity in adults. Res Sports Med. 2020;28(1):15-26. http://doi.org/10.1080/15438627.2018.1502183
Taverna MJ, Martínez-Larrad MT, Frechtel GD, Serrano-Ríos M. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur J Endocrinol. 2011;164(4):559-567. http://doi.org/10.1530/eje-10-1039
Amato MC, Giordano C, Galia M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920-922. http://doi.org/10.2337/dc09-1825
Shin KA, Kim YJ. Usefulness of surrogate markers of body fat distribution for predicting metabolic syndrome in middle-aged and older Korean populations. Diabetes Metab Syndr Obes. 2019;12:2251-2259. http://doi.org/10.2147/dmso.S217628
Jeong S, Lee JH. The verification of the reliability of a triglyceride-glucose index and its availability as an advanced tool. Metabolomics. 2021;17(11):97. http://doi.org/10.1007/s11306-021-01837-9
Er LK, Wu S, Chou HH, et al. Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals. PLoS One. 2016;11(3):e0149731. http://doi.org/10.1371/journal.pone.0149731
Patel CJ, Pho N, McDuffie M, et al. A database of human exposomes and phenomes from the US National Health and Nutrition Examination Survey. Sci Data. 2016;3:160096. http://doi.org/10.1038/sdata.2016.96
Liu PJ, Lou HP, Zhu YN. Screening for metabolic syndrome using an integrated continuous index consisting of waist circumference and triglyceride: a preliminary cross-sectional study. Diabetes Metab Syndr Obes. 2020;13:2899-2907. http://doi.org/10.2147/dmso.S259770
Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:26. http://doi.org/10.1186/1471-2261-5-26
Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299-304. http://doi.org/10.1089/met.2008.0034
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. http://doi.org/10.1007/bf00280883
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-3672. http://doi.org/10.1210/jcem.84.10.6079
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. http://doi.org/10.1016/j.juro.2018.03.115
Li Y, Zheng R, Li S, et al. Association between four anthropometric indexes and metabolic syndrome in US adults. Front Endocrinol. 2022;13:889785. http://doi.org/10.3389/fendo.2022.889785
Alizargar J, Bai CH, Hsieh NC, Wu SV. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol. 2020;19(1):8. http://doi.org/10.1186/s12933-019-0982-2
Sun K, Wang C, Lao G, et al. Lipid accumulation product and late-onset hypogonadism in middle-aged and elderly men: results from a cross-sectional study in China. BMJ Open. 2020;10(2):e033991. http://doi.org/10.1136/bmjopen-2019-033991
Caretta N, Facondo P, Mereu S, et al. Cardiometabolic indices predict hypogonadism in male patients with type 2 diabetes. J Endocrinol Invest. 2022. http://doi.org/10.1007/s40618-022-01941-0
Rotter I, Rył A, Grzesiak K, et al. Cross-sectional inverse associations of obesity and fat accumulation indicators with testosterone in non-diabetic aging men. Int J Environ Res Public Health. 2018;15(6):1207. http://doi.org/10.3390/ijerph15061207
Maturana MA, Moreira RM, Spritzer PM. Lipid accumulation product (LAP) is related to androgenicity and cardiovascular risk factors in postmenopausal women. Maturitas. 2011;70(4):395-399. http://doi.org/10.1016/j.maturitas.2011.09.012
Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol. 2009;5(12):673-681. http://doi.org/10.1038/nrendo.2009.212
Shi Z, Araujo AB, Martin S, O'Loughlin P, Wittert GA. Longitudinal changes in testosterone over five years in community-dwelling men. J Clin Endocrinol Metab. 2013;98(8):3289-3297. http://doi.org/10.1210/jc.2012-3842
Pintana H, Chattipakorn N, Chattipakorn S. Testosterone deficiency, insulin-resistant obesity and cognitive function. Metab Brain Dis. 2015;30(4):853-876. http://doi.org/10.1007/s11011-015-9655-3
Vignozzi L, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012;212(1):71-84. http://doi.org/10.1530/joe-11-0289
Filippi S, Vignozzi L, Morelli A, et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med. 2009;6(12):3274-3288. http://doi.org/10.1111/j.1743-6109.2009.01467.x
Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013;217(3):R25-R45. http://doi.org/10.1530/joe-12-0455
Vinson GP, Bell JB, Whitehouse BJ. Production of testosterone and corticosteroids by the rat adrenal gland incubated in vitro and the effects of stimulation with ACTH, LH and FSH. J Steroid Biochem. 1976;7(5):407-411. http://doi.org/10.1016/0022-4731(76)90103-5
Fui MN, Dupuis P, Grossmann M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J Androl. 2014;16(2):223-231. http://doi.org/10.4103/1008-682x.122365
Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(11):5462-5468. http://doi.org/10.1210/jc.2004-0804
Salter CA, Mulhall JP. Guideline of guidelines: testosterone therapy for testosterone deficiency. BJU Int. 2019;124(5):722-729. http://doi.org/10.1111/bju.14899
Liu N, Luo X, Li P, Xiong W. The triglycerides and glucose Index is not superior to HOMA-IR in predicting testosterone deficiency among adult males. Andrology. 2023;11(2):215-224. http://doi.org/10.1111/andr.13207
Zhang K, Chen Y, Liu L, et al. The triglycerides and glucose index rather than HOMA-IR is more associated with Hypogonadism in Chinese men. Sci Rep. 2017;7(1):15874. http://doi.org/10.1038/s41598-017-16108-8